Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.
You may also be interested in...
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.
Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.